oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2020 ( 123 )

2019 ( 670 )

2018 ( 720 )

2017 ( 710 )

Custom range...

Search Results: 1 - 10 of 412361 matches for " Moisés Monta?o Bermúdez "
All listed articles are free for downloading (OA Articles)
Page 1 /412361
Display every page Item
Efectos de la densidad por corral sobre la producción y las concentraciones sanguíneas de metabolitos y cortisol en cerdos en crecimiento y fi nalización
Miguel Gerardo Hernández Castorena,María de Lourdes ángeles,Laura Zapata Salinas,Moisés Montao Bermúdez
Veterinaria México , 2006,
Abstract: El objetivo fue evaluar la reducción de espacio de piso debido al incremento de cerdos por corral, sobre el consumo de alimento (CDA), ganancia de peso (GDP) y efi ciencia alimentaria (EA) y las concentraciones séricas de glucosa, urea y cortisol en cerdos en crecimiento y fi nalización. Se usaron 120 cerdos en crecimiento y 64 en fi nalización que se aleatorizaron a tres densidades: 1) = un cerdo alojado individualmente con 2.5 m2 disponibles de piso; 2) = seis cerdos en crecimiento o cuatro en fi nalización alojados en grupo con 0.94 y 1.41 m2 disponibles de piso por cerdo; 3) = 12 cerdos en crecimiento u ocho en fi nalización alojados en grupo con 0.47 y 0.71 m2 disponibles de piso por cerdo. Las concentraciones séricas de glucosa, urea y cortisol se determinaron al inicio del experimento y al fi nal de las semanas uno, tres y cinco. En crecimiento, el CDA (P < 0.05) y GDP (P < 0.10) fueron mayores en la densidad 1 en comparación con las densidades 2 y 3; la EA fue mayor (P < 0.10) en la densidad 2 que en las densidades 1 y 3. En fi nalización, el CDA y GDP (P < 0.10) fueron mayores en la densidad 1, en comparación con las densidades 2 y 3. Las concentraciones de glucosa, urea y cortisol no fueron diferentes entre densidades. El consumo de alimento y la ganancia de peso disminuyeron al aumentar la densidad, pero esta disminución no estuvo relacionada con cambios en las concentraciones séricas de algunos indicadores de estrés como glucosa, urea o cortisol.
Comparison of models for the estimation of variance components for growth traits of registered limousin cattle
Ríos-Utrera, ángel;Vega-Murillo, Vicente Eliezer;Martínez-Velázquez, Guillermo;Montao-Bermúdez, Moisés;
Tropical and subtropical agroecosystems , 2011,
Abstract: six models to estimate genetic parameters for birth weight (bw), weaning weight adjusted to 205 days (w205), and yearling weight adjusted to 365 days (w365) were compared. model a included direct genetic effects. model ap allowed for direct genetic and permanent environmental effect of the dam. model am included direct genetic and maternal genetic effects. models amc and amp were the same as model am but they also allowed for the covariance between direct and maternal genetic effects, and the common environmental effect due to the dam, respectively; and model amcp was fitted for all three random effects plus the covariance between direct and maternal effects. models were compared using the likelihood ratio text. the amc model was selected to be the most appropriate for bw and w205, whereas model a was chosen for w365. when maternal effects were included, direct genetic variance and direct heritability estimates were reduced for bw and w205. direct heritability estimates with appropriate models were: 0.13, 0.21 and 0.20 for bw, w205 and w365. heritability of maternal effects with appropriate models was: 0.15 and 0.32 for bw and w205, and direct-maternal genetic correlations with appropriate models were: -0.67 and -0.69 for bw and w205, respectively.
Desarrollo e implementación de una vía clínica a los pacientes que inician la hemodiálisis de forma programada
Navarro Bermúdez,Moisés;
Revista de la Sociedad Espa?ola de Enfermería Nefrológica , 2011, DOI: 10.4321/S1139-13752011000100003
Abstract: a clinical pathway aims to be an institutionalized instrument, where all the professionals of the service know at all times the activities and actions they have to carry out, the time this care activity lasts, and users and relatives know right from the start all the information on the care they will be given. in order to design a clinical pathway, a multidisciplinary working group was formed which drew up an instrument made up of: ? a time chart detailing by day the activities of all the professionals involved in the clinical pathway, and specifying other important aspects such as complementary tests, diet and medication. ? variance sheet. where both deviations from the pathway and the actions realized or their justification are detailed. ? information sheet for the patient and/or relative. it includes a series of illustrations that inform the patient of the most common evolution of the process. it is a simplified graphic version of the time chart so that it can be easily understood by the patient. ? patient and/or relative satisfaction survey. this is given to the patient so that he or she can give his or her opinion anonymously on the care received. it includes questions on the information received, care, catering aspects, etc. we have considered the entire team, and reassessed the pathway when we reached 10 patients, in order to make modifications or determine areas for improvement.
Desarrollo e implementación de una vía clínica a los pacientes que inician la hemodiálisis de forma programada Development and implementation of a clinical pathway for patients starting programmed haemodialysis
Moisés Navarro Bermúdez
Revista de la Sociedad Espa?ola de Enfermería Nefrológica , 2011,
Abstract: Una vía clínica pretende ser un instrumento institucionalizado, donde todos los profesionales del servicio sepan en todo momento todas las actividades y acciones que tienen que llevar a cabo el tiempo que dura esta actividad asistencial y los usuarios/familiares conozcan desde el primer momento toda la información de la asistencia que se les va a prestar. Con el fin de dise ar una vía clínica se formó un grupo de trabajo interdisciplinar que elaboró un instrumento compuesto por: Una matriz temporal, donde se detallan por día las actividades de todos los profesionales implicados en la vía clínica, y se especifican otros aspectos importantes como son las pruebas complementarias, dieta y medicación. Hoja de variaciones. Donde se detallan tanto las desviaciones de la vía como las acciones realizadas o su justificación. Hoja de información al paciente y/o familiar. Incluye una serie de ilustraciones que informan al paciente sobre la evolución más frecuente del proceso. Es una versión gráfica simplificada de la matriz para una fácil comprensión del paciente. Encuesta de satisfacción del paciente y/o familiar. Se entrega al paciente para que exprese de forma anónima su opinión sobre la atención y cuidados prestados. Engloba preguntas respecto a la información recibida, la atención, aspectos de hostelería, etcétera. Hemos considerado todo el equipo, como periodo de reevaluación de la misma cuando alcancemos los 10 pacientes, para poder realizar modificaciones o áreas de mejoras de la misma. A clinical pathway aims to be an institutionalized instrument, where all the professionals of the service know at all times the activities and actions they have to carry out, the time this care activity lasts, and users and relatives know right from the start all the information on the care they will be given. In order to design a clinical pathway, a multidisciplinary working group was formed which drew up an instrument made up of: A time chart detailing by day the activities of all the professionals involved in the clinical pathway, and specifying other important aspects such as complementary tests, diet and medication. Variance sheet. Where both deviations from the pathway and the actions realized or their justification are detailed. Information sheet for the patient and/or relative. It includes a series of illustrations that inform the patient of the most common evolution of the process. It is a simplified graphic version of the time chart so that it can be easily understood by the patient. Patient and/or relative satisfaction survey. This is given to the
Revisión de la vía clínica "inicio programado en hemodiálisis" Review of the "Programmed haemodialysis start" clinical patway
Moisés Navarro Bermúdez
Enfermería Nefrológica , 2012,
Abstract:
Por qué y cómo hemos de analizar los cálculos urinarios
Gràcia-Garcia,S.; Millán-Rodríguez,F.; Rousaud-Barón,F.; Monta?és-Bermúdez,R.; Angerri-Feu,O.; Sánchez-Martín,F.; Villavicencio-Mavrich,H.; Oliver-Samper,A.;
Actas Urológicas Espa?olas , 2011, DOI: 10.4321/S0210-48062011000600008
Abstract: context: there is heterogeneity of criteria on the utility of urinary stone analysis as well as on which is the most suitable methodology. this review presents the analysis of the lithiasis using the morphoconstitutional analysis technique based on the combination of the stereoscopic microscopy (sm) with infrared study (irs). summary of the evidence: there are many techniques to analyze the stone: chemical analysis, electron microscopy, x-ray diffraction, sm and irs. reviewing each one of these techniques and through the study of several clinical cases, this review shows the usefulness of stone analysis and the pros and cons of each one of the mentioned techniques. furthermore, it can be clearly seen how the morphoconstitutional analysis is the one that offers the most useful clinical information to the urologist. in addition, classification of the lithiasis based on this method and its clinical correlation with patients is presented. conclusions: using the morphoconstitutional study to analyze the stone offers more information than the other techniques and it makes it possible to establish a stone classification of important clinical and diagnostic utility.
Plan de cuidados a una paciente con una fractura pertrocantérea Care plan for patient with a pertrochanteric fracture
Antonia Herrerapicazo Benítez,Moisés Navarro Bermúdez
Revista de la Sociedad Espa?ola de Enfermería Nefrológica , 2010,
Abstract:
Fármacos de primera línea utilizados en el tratamiento de la tuberculosis
Silva,Carlos; Bermúdez,Valmore; Arraiz,Naylet; Bermúdez,Fernando; Rodríguez,Moisés; Valdelamar,Lisney; Leal,Elliuz;
Archivos Venezolanos de Farmacología y Terapéutica , 2007,
Abstract: tuberculosis has emerged as an enormous global public health epidemic. worldwide, it is the second leading infectious cause of death, after hiv infection. the world health organization has estimated that every year, about 8 million persons develop active tuberculosis, and more than 2 million persons die from the disease. the goals of antituberculosis therapy are to ensure a cure without relapse, to prevent death, to stop transmission of m. tuberculosis, and to prevent the emergence of drug-resistant disease. therapy is initiated with a multidrug regimen to kill tubercle bacilli rapidly, to minimize or prevent the development of drug-resistant m. tuberculosis strains, and to eliminate persistent organisms from host tissue to prevent relapse. tuberculosis requires prolonged treatment. the minimum length of therapy for the treatment of drug-susceptible tuberculosis is 6 to 9 months with a rifampin-based regimen (so-called short-course therapy). longer courses of therapy are required for drug-resistant tuberculosis, especially multidrug-resistant disease (i.e., disease caused by m. tuberculosis that is resistant to at least isoniazid and rifampin). treatment of tuberculosis has two phases: initiation (also known as the bactericidal or intensive phase) and continuation (also known as the subsequent sterilizing phase). the aim of this article is to study the pharmacologic management of this entity focusing on standard antimicobacterial therapy.
Tratamiento farmacológico de la obesidad: presente, pasado y futuro
Lisney Valdelamar,Moisés Rodríguez,Valmore Bermúdez,Elliuz Leal
Archivos Venezolanos de Farmacología y Terapéutica , 2007,
Abstract: La obesidad es una enfermedad endocrino-metabólica caracterizada por excesiva acumulación de grasa en el tejido adiposo. La importancia en el estudio y tratamiento de la obesidad, radica no sólo en la alta incidencia de ésta patología en los últimos a os, sino el alto riesgo en salud que ésta implica. El objetivo del tratamiento es revertir el balance energético positivo, y mejoramiento de las co-morbilidades asociadas, mediante la reducción de la ingesta de alimentos y el aumento del gasto energético. Los pilares de la terapéutica son modificar la conducta, dieta y ejercicios. Sin embargo estas no son herramientas que garantizan el mantenimiento de la pérdida de peso a largo plazo sin efecto rebote. Los fármacos constituyen una herramienta empleada en asociación con los anteriores y no como única medida. Los fármacos para el tratamiento de la obesidad, se clasifican en aquellos que reducen la ingesta de alimentos (agentes noradrenérgicos, serotoninérgicos y duales), disminuyen la absorción (orlistat) y los que incrementan la termogénesis (efedrina y cafeína). En la actualidad sólo sibutramina y orlistat se vislumbran como las únicas drogas cuya seguridad y eficacia demostrada permiten su aplicación clínica a largo plazo (2 a os). Los avances en el estudio del balance energético y su regulación han postulado nuevos blancos para la fabricación de futuros fármacos más específicos y eficaces como los antagonistas de receptores endocanabinoides. Obesity is a chronic, stigmatized and costly disease that is rarely curable and is increasing in prevalence in most of the world. At this time, available treatments, including drugs, are palliative and are effective only while the treatment is being actively used; when effective drugs or other treatments are discontinued, weight gain is an inevitable consequence. Any effective drug will be widely used for its cosmetic as well as medical benefits, as obesity is a socially stigmatized problem. Thus, any drug that is approved should meet high standards for safety. Obesity prevention and management should be given as much priority and skill by all professionals as it would be given to any other common chronic disease with such serious consequences. Several pharmacological approaches have been proposed to promote weight loss and/or minimize weight regain and the need for and logic of anti-obesity drug treatment has been recognized. While the pharmacological market of anti-obesity drugs remained almost unchanged for several decades, the last years has been characterized by three major events: first, the withdrawal, bec
Actuaciones y cuidados enfermero en diálisis para pacientes con intoxicación de litio
Ma Carmen Mariscal Ordó?ez,Isabel Resille Gil,Moisés Navarro Bermúdez
Enfermería Nefrológica , 2012,
Abstract:
Page 1 /412361
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.